Rockwell Medical, Inc. (RMTI) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Rockwell Medical, Inc. is a healthcare company developing, manufacturing, and distributing hemodialysis products, primarily liquid and dry acid/bicarbonate concentrates. The company operates in a single reportable segment. During the quarter, the company concluded manufacturing operations at its Greer, South Carolina facility to streamline operations.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Sales | $15.9 million | $28.3 million | $50.9 million | $76.8 million |
| Gross Profit | $2.3 million | $6.2 million | $7.8 million | $13.9 million |
| Gross Margin | 14% | 22% | 15% | 18% |
| Operating Loss | $(1.6) million | $1.9 million | $(4.3) million | $1.1 million |
| Net Loss | $(1.8) million | $1.7 million | $(4.8) million | $0.3 million |
| Cash & Equivalents | $13.6 million (as of Sept 30, 2025) | |||
| Total Investments (AFS) | $10.1 million (as of Sept 30, 2025) | |||
| Long-Term Debt (Net) | $8.7 million (as of Sept 30, 2025) | |||
| Net Working Capital | $27.9 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 44% in Q3 and 34% YTD compared to 2024. The primary driver was a significant reduction in sales to major customer DaVita, Inc., which represented 52% of Q3 2024 revenue but only 12% of Q3 2025 revenue. DaVita is transitioning to a new supplier.
- Margin Compression: Gross margin declined from 22% to 14% in Q3. This was due to lower sales volume, the absence of a special large premium-priced order from DaVita in the prior year, and increased costs related to the closure of the South Carolina facility (severance and closure costs).
- Profitability Shift: The company swung from a net income of $1.7 million in Q3 2024 to a net loss of $1.8 million in Q3 2025. YTD 2025 shows a net loss of $4.8 million compared to a net income of $0.3 million in YTD 2024.
- Capital Activity: The company raised approximately $7.8 million in net proceeds through its At-The-Market (ATM) facility during the nine months ended September 30, 2025. Approximately $13.1 million remains available under the ATM facility.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash, cash equivalents, and investments ($23.7 million total) are sufficient to meet operating requirements for at least the next 12 months. The company is in compliance with all debt covenants under its amended loan agreement with Innovatus, which extends the maturity to January 1, 2029, with an interest-only period through 2027.
- DaVita Transition: While DaVita has agreed to non-refundable payments totaling $1.7 million during the nine months ended Sept 30, 2025 to ensure supply continuity, the company is no longer the primary supplier. Discussions regarding future volume commitments or contract extensions are ongoing but uncertain.
- New Business: In Q2 2025, the company secured a multi-year product purchase agreement with Innovative Renal Care (IRC), a major dialysis provider, to supply concentrates and mixers.
- Restructuring: The closure of the Greer, SC facility is expected to be substantially completed by December 31, 2025. No impairment losses were recorded as assets were fully depreciated or transferred.
- Risks: Key risks include the inability to replace DaVita volume, the need for additional capital if operational plans are not met, and general macroeconomic instability affecting credit markets and supply chains.
Investor Verification Checklist
- Verify the status of ongoing negotiations with DaVita regarding future volume commitments or contract extensions.
- Monitor the execution of the new agreement with Innovative Renal Care (IRC) and its impact on revenue stabilization.
- Track the utilization of the remaining $13.1 million ATM facility and any potential dilution from future equity raises.
- Review the timeline and cost savings realization from the South Carolina facility closure.
- Assess the company's ability to maintain compliance with Innovatus loan covenants given the current revenue trajectory.